Chunk #27 — 3. Pharmacogenetic Studies of Treatment for Alcohol Use Disorder in Individuals of Diverse Ancestries — 3.3 Individuals of African Ancestry
Asp40 allele has been shown to be <5% in individuals of African ancestry44, which could account for the poor treatment response to NTX in this study. A subsequent alcohol challenge study in social drinkers of African ancestry also did not find an effect of NTX on any subjective measures of alcohol-related effects.55 However, once again, genetic moderation was not examined, nor have there been any alcohol-related challenge studies conducted in AD individuals of African ancestry. These two studies highlight both the potential lack of NTX’s effect in patients of African ancestry, in addition to the unmet need for testing FDA-approved (e.g. acamprosate, disulfiram, NTX), and non-FDA approved (i.e. sertraline, topiramate) medications for the treatment of AUD in individuals of African ancestry, as NTX remains the only medication tested to date.
